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Abstract
Background: In China, primary EBV infection occurs during childhood with seroprevalence reaching about 100% by
10 years of age. There are few studies on EBV variants in diseases associated with EBV infection in Chinese children. In
this study, we investigated the diversity of the EBV genes (EBNA-1 and LMP-1) and the relationship between EBV
variants and the clinical phenotypes in diseases associated with EBV infections in Chinese pediatric cases.
Results: The frequencies of EBV type I in the IM, HLH and HL samples were 98.4%, 100% and 95.8%, respectively.
Three known EBNA-1 variants were identified, including V-val (all were V-val-v1 sub-variant), P-thr’ and V-Leu (MT).
The frequency of V-val-v1 was 98.6% in the IM samples, 100% in the HLH samples and 97.1% in the HL samples.
There were no significant differences of the distribution of EBNA-1 variants between IM, HLH and HL samples (P >
0.05). Three known LMP-1 variants, including China 1, China 2 and Med, were identified and China 1 was
predominant in all groups (IM 88.6%, HLH 100% and HL 100%). The frequency of del-LMP-1 was 88.6% in the IM
samples, 100% in the HLH samples and 96.0% in the HL samples. There were no significant differences in the
frequency of del-LMP-1 between the IM, HLH and HL samples (P > 0.05). The frequency of XhoI loss was 90.6% in
the IM samples, 100% in the HLH samples and 100% in the HL samples, with no significant difference in frequency
(P > 0.05). In the EBV type I strain, V-val-v1 variant (EBNA-1) was linked with China1 variant (LMP-1) in 88.9% of the
IM samples, 100% of the HLH samples and 80.0% of the HL samples in this study.
Conclusions: Type I EBV was the most prevalent subtype EBV in Chinese pediatric cases and V-val-v1 (EBNA-1) and
China1 (LMP-1) variants were the most dominant variants. There was a strong linkage between V-val-v1 (EBNA-1)
variant and China1 (LMP-1) variant in type I EBV. The sequence variation in EBV genes may represent a geographic
polymorphism since no preferential associations were found between specific EBV variants and specific diseases in
this study.
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Background
Epstein-Barr virus (EBV) is a lymphotrophic human
gamma-1 herpes virus with a double stranded DNA
genome comprised of approximately 170-kilobases. It is
transmitted primarily through saliva and infects over
95% of the world’s population [1]. In developing coun-
tries, primary EBV infection typically occurs in early
childhood and is asymptomatic; in developed countries,
infection occurs in later childhood or young adulthood
and can manifest as infectious mononucleosis (IM),
which is self-limiting. EBV is associated with not only
nonmalignant diseases but also a number of malignant
diseases, including Burkitt’s lymphoma, nasopharyngeal
carcinoma and Hodgkin lymphoma.
After primary infection, EBV establishes a lifelong
latent infection in B lymphocytes [2]. During latent
infection, EBV expresses a restricted set of genes,
including two EBV-encoded RNAs (EBER-1 and EBER-
2), six EBV nuclear antigens (EBNA-1, EBNA-2, EBNA-
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integral membrane proteins (LMP-1, LMP-2A and -2B).
Based on the sequence divergence of nuclear antigens
(EBNA-2, -3A, -3B, and -3C) EBV can be divided into
two types of EBV: type I and type II [3,4]. Detailed
sequence analysis has also been done with the EBNA-1,
LMP-1 and BZLF1-genes, which are not type-specific in
their sequence divergence among EBV strains.
EBNA-1 sequence variation has been described by
comparing the sequence of several EBV isolates from
tumors and cell lines with the sequence of prototype
B95-8 [5]. EBV has been classified into five EBNA-1 var-
iants based on polymorphism of the C-terminal region
and the signature changes at amino acid residue 487 of
EBNA-1, including the prototype P-ala and P-thr var-
iants and the V-val, V-leu and V-pro variants [6].
LMP-1 gene polymorphisms were identified in several
studies [7-11]. The most common polymorphisms con-
tain substitutions of the nucleotides or amino acids
including loss of restriction sites (such as XhoIi nt h e
N-terminus), variations of the number of 33 bp repeats,
and a 30 bp deletion in the C-terminus (del-LMP-1).
Ten major variants of LMP-1 (China 1, China 2, China
3, NC (North Carolina), Mediterranean+ (Med+), Med-,
GD1, SEA 1, and SEA 2) have been described from dif-
ferent regions and diseases [8-10].
In China, primary EBV infection occurs during child-
hood with seroprevalence reaching about 100% by 10
years of age. However there are few studies on EBV var-
iants in diseases associated with EBV infection in Chi-
nese pediatric population [12]. So in this study, we
investigated the diversity of the EBV genes EBNA-1 and
LMP-1 in IM (a self-limiting disease), EBV associated
Hemophagocytic lymphohistiocytosis (EBV-HLH) (a
severe hematological dise a s et r i g g e r e db yE B V )a n d
Hodgkin lymphoma (HL) in Chinese children.
Results
EBV types I and II in EBV associated diseases in children
The frequency of EBV type I or type II infection was
determined in 107 samples. Type I EBV was present in
105 samples (98.1%, 105/107) and type II EBV in 2 sam-
ples (1.9%, 2/107) (Table 1).
EBNA-1 variants in EBV associated diseases in children
The C-terminal EBNA-1 fragment was amplified from
128 samples (Table 2). In this study, three known
variants of the EBNA-1 including V-val (all were V-val-
v1 Sub-variant), P-thr’ and V-Leu (MT) [13-15] were
observed (Table 2). Sub-variant V-val-v1 of EBNA-1
first reported by Do et.al [13] was the most common in
the three groups (IM 98.6%, HLH 100%, HL 97.1%).
There were no significant differences in the incidence of
EBNA-1 variants between the IM, HLH and HL samples
(P > 0.05).
LMP-1 variants in EBV associated diseases in children
A total of 74 LMP-1 nucleotide sequences correspond-
ing to the carboxyl-terminal were obtained and trans-
lated into amino acid for the phylogenetic analysis
(Figure 1). Three known variants of LMP-1 including
China 1, China 2 and Med were identified (Table 3).
Among them China 1 was predominant in all groups.
The frequency of China 1 in the IM, HLH and HL sam-
ples was 88.6% (39/44), 100% (25/25) and 100% (5/5),
respectively.
A short fragment of LMP-1 containing the 30 bp dele-
tion region was amplified from 20 paraffin-embedded
tumors biopsies. Nineteen of them contained the del-
LMP-1, and 1 specimen had wild type LMP-1 (wt-LMP-
1). In total, the del-LMP-1 was detected in 88.6% (39/
44) of IM samples, 100% (25/25) HLH samples and
96.0% (24/25) HL samples. There were no significant
differences of the incidence of del-LMP-1 in three
groups (P > 0.05).
The full length of LMP-1 was amplified in 54 samples.
LMP-1 variant with XhoI loss was detected in 90.6%
(29/32) of the IM, 100% (17/17) of the HLH and 100%
(5/5) of the HL samples, respectively. There was no sig-
nificant difference in the frequency of XhoI loss between
the IM and HLH samples, or between the IM and HL
samples (P > 0.05).
Linkage analysis
A combination of more than one polymorphic site in
the EBV genome was investigated in 60 samples for this
study. All 60 samples were EBV type I strains. The fre-
quency of V-val-v1 (EBNA-1) variant lingking China1
(LMP-1) variant in the IM, HLH and HL samples was
88.9% (32/36), 100% (19/19) and 80.0% (4/5), respec-
tively (Table 4). Preferential linkages of certain EBNA-1
variants to distinct LMP-1 diversity were found to exist.
However, there were no significant differences between
Table 1 Distribution of EBV subtypes in IM, HLH and HL
patients
EBV subtypes IM (n = 61) HLH (n = 22) HL (n = 24)
Type I 60 (98.4%) 22 (100%) 23 (95.8%)
Type II 1 (1.6%) 0 1 (4.2%)
Table 2 Distribution of EBNA-1 variants in IM, HLH and
HL patients
variants IM (n = 71) HLH (n = 23) HL (n = 34)
V-val-v1 70(98.6%) 23 (100%) 33 (97.1%)
P-thr’ 1(1.4%) 0 0
V-Leu(MT) 0 0 1 (2.9%)
Ai et al. Virology Journal 2012, 9:13
http://www.virologyj.com/content/9/1/13
Page 2 of 8the distribution of linked EBV genes in the IM, HLH
and HL samples (P > 0.05).
Discussion
EBV is a lymphotrophic human gamma-1 herpes virus.
It is classified as EBV types I and II based on sequence
variation in the EBNA2 and EBNA3 genes [3,4]. Pre-
vious studies of healthy Asian populations showed that
Figure 1 Phylogenetic tree of the C-terminus of LMP-1. B95-8 variant according to Genebank: V01555.2. China 1 (Genebank: AY337723.1),
China 2 (Genebank: AY337724.1), Alaskan (Genebank: AY337725.1), Med- (Genebank: AY337721.2), Med+ (Genebank: AY337722.2) and North
Carolina (NC) (Genebank: AY337726.2) are the LMP-1 variants according to Miller et al.(1994), Sung et al.(1998) and Edwards et al (1999). IM:
infectious mononucleosis; HLH: hemophagocytic lymphohistiocytosis. ‘m’ indicated the outpatient and the figure means the mumber of the
sample.
Table 3 Distribution of LMP-1 variants in IM, HLH and HL
patients
variants IM (n = 44) HLH (n = 25) HL (n = 5)
China1 39 (88.6%) 25 (100%) 5 (100%)
China2 3 (6.8%) 0 0
Med 2 (4.6%) 0 0
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with EBV type II and 11% with both types [16-18]. In
this study, the frequencies of EBV type I in IM, HLH
and HL were 98.4%, 100% and 95.8%, respectively. No
co-infection with both viral types was detected. This dif-
ference can be explained by the small number of sam-
ples analyzed in this work, or alternatively, that pediatric
patients are still not subjected to subsequent re-infec-
tions as adults [1].
EBNA-1 is the only latent protein that is consistently
expressed in all EBV-positive malignancies. EBNA-1 is
critical in maintaining EBV in the infected cells and
facilitating episomal replication [19,20]. In replicating
latently infected EBV cells, EBNA-1 dictates equal parti-
tioning of EBV genome, thus reducing the loss of EBV
infected cells [21]. EBNA-1 is also a transcriptional acti-
vator and activates expression of EBV transcripts via the
latent C promoter [22]. EBNA-1 carboxy (C)-terminal
sequence variants have been described based on the
amino acid signature at codon 487, and designated pro-
totype including P-ala (identical to prototype B95.8
strain), P-thr, and variant including V-val, V-leu, and V-
pro [6]. New variants and subvariants have more
recently been characterized [1,13,23].
In Asian, most studies of the EBNA-1 variations have
focused on nasopharyngeal carcinoma (NPC). Mai et al.
suggested that V-val EBNA-1 with the functional advan-
tage compared with prototype shown in their study
might contribute to the tumorigenesis of NPC by
increasing the expression of itself or other viral or cellu-
lar genes [24]. Zhang et al. indicate that V-val variant
infects NPC preferentially and that a susceptibility to a
particular EBV isolate in the nasopharynx may exist dur-
ing development of NPC [25]. However, Sandvej et al.
found that V-val is the dominant variant in Asian
regions and appear to be associated with Asian NPC
patients but not found in Danish NPC biopsies [23]. Do
et al. reported that V-val-v1 (EBNA-1) is predominant
in NPC as well as in healthy EBV-carriers from an
Asian population [13]. Wang et al. observed that V-val
was the most common variant not only in NPC but also
in EBV associated gastric carcinoma and healthy donors
in Northern China [26]. Moreover, a review about
genetic diversity of EBV showed that V-val was detected
in both cases and controls almost exclusively in China
[27].
IM is a self-limiting disease caused by primary EBV
infection. EBV-HLH is a severe hematological disease
triggered by EBV infection and HL is a malignant dis-
ease. In this study, the percentage of V-val-v1 (EBNA-1)
in IM, HLH and HL were 98.6%, 100% and 97.1%,
respectively. No significant differences were found in the
incidence of V-val-v1 subvariant in IM, HLH and HL
groups (P > 0.05). The results indicated that the V-val-
v1 is the dominant variant in Chinese pediatric cases,
and EBNA-1 polymorphism may represent a geographic
polymorphism. The data from Argentinean pediatric
population showed that V-leu sub-variants preferentially
circulate in this region. Interestingly, they also favor the
geographical association hypothesis since no evidence
for a preferential compartment distribution of EBNA-1
variants and sub-variants was found [1].
LMP-1 is considered the EBV oncogene [28]. It
encompasses a 25 aa N-terminus, six predicted trans-
membrane domains (aa: 26-196), and a C-terminus (aa:
197-386). Both the N- and C-termini are located in the
cytoplasm of the cell [29,30]. The C-terminus interacts
with cellular proteins through the C-Terminal Activa-
tion Region 1 (CTAR1) and CTAR2 and activates sev-
eral signaling pathways, including the transcriptional
nuclear factor-kB (NF-kB) whose activation is linked to
the inhibition of apoptosis [31,32]. The most commonly
reported LMP-1 gene polymorphisms was a 30 bp dele-
tion in the C-terminus. The 30 bp deletion variant (del-
LMP-1) was first detected in EBV isolated from cell
lines derived from NPC patients from Southern China
[33]. China 1 and Med+ variants have this 30 bp
deletion.
A number of reports have focused on the del-LMP-1
variant in malignant diseases. Hadhri et al. found that
del-LMP-1 variant was significantly (P = 0.006) more
frequent in NPC (71.42%) than in control biopsies (52%)
in Tunisia [34]. Tiwawech et al. also reported that a sig-
nificant association between the del-LMP-1 variant and
NPC susceptibility (P = 0.023) was exist in Thais. More-
over, the frequency of del-LMP-1 in NPC patients was
Table 4 Linkage analysis of EBV type, EBNA-1 and LMP-1 variants
EBV type EBNA-1 variant LMP-1 variant Number of Cases (%)
IM HLH HL
Type I (60) V-val-v1 China1 32 (88.9%) 19 (100%) 4 (80.0%)
China2 2 (5.6%) 0 0
Med 1 (2.8%) 0 0
P-Thr’ China1 1 (2.8%) 0 0
V-Leu(MT) China1 0 0 1 (20.0%)
Type2 (0) 0 0 0 0 0
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from South America (35 Brazilian HD patients and 27
Argentine pediatric patients of HD) show that del-LMP-
1 was more frequently detected in Hodgkin’s lymphoma
than in non-neoplastic controls (P = 0.005) suggesting a
pathogenic role of del-LMP-1 variant in Hodgkin’sl y m -
phoma in this region [35]. These results supporting the
idea that EBV del-LMP-1 may be a disease-associated
variant.
H o w e v e r ,t h e r ew e r es o m ec o n troversial findings. See
et al. concluded that the presence of del-LMP-1 was
associated with the Chinese race [36]. Saechan et al.
found a higher prevalence (P = 0.026) of del-LMP-1 var-
iant in Southern Thais than in Central Thais [9]. In this
study, there was no significant difference in the fre-
quency of del-LMP-1 between the IM, HLH and HL
samples (P > 0.05) in Chinese children. And the same
trend was also observed in another study in China, with
83% of Hodgkin’s lymphoma and 86% of healthy con-
trols showing del-LMP-1 variant [37]. Thus, the del-
LMP-1 variant may represent a geographic or race asso-
ciated polymorphism.
The loss of XhoI restriction site in the N-terminus of
the LMP-1 gene is another commonly reported LMP-1
gene polymorphism. Hu et al. first described the loss of
the XhoIs i t ef r o me x o n1o ft h eL M P - 1g e n ei nt h e
CAO cell line derived from a Chinese NPC case [28].
The loss of the XhoIs i t ei sc a u s e db yas i n g l eb a s es u b -
stitution from G to T at the nucleotide position 169425.
It has been reported that the XhoI loss was significantly
associated with Asian NPC patients and the XhoIl o s s
has been considered as a specific HL marker [28,38,39].
However, See et al. found that the XhoIl o s sw a sn o t
only associated with type III NPC, but also with the
Chinese race [36]. In this study the frequency of XhoI
loss was 90.6% in the IM samples, 100% in the HLH
samples and 100% in the HL samples. There was no sig-
nificant difference in the frequency of XhoI loss between
the IM and HLH samples or the IM and HL samples (P
> 0.05). These findings suggest that the loss of XhoI site
may not be a polymorphism associated with disease
phenotypes.
Studies conducted to date have focused on EBV within
different polymorphic regions, making comparisons
across studies difficult and limiting the ability to define
the full spectrum of diversity within the EBV genome
[27]. Thus, a combination of more than one poly-
morphic site in the EBV genome might be involved in
determining disease characteristics. This study showed a
high linkage between V-val-v1 variant (EBNA-1) and
China1 variant (LMP-1) in type I EBV strains. There
were no significant differences between the distribution
of the linkage in the IM, HLH and HL samples (P >
0.05).
T h e r ew e r es o m el i m i t a t i o n so ft h i ss t u d y .B e c a u s eo f
relatively small size of samples, some variants, such as
P-thr, was detected with very low positive rate compared
with previous study in this region. Some blood samples
may harbor a lower level of viral load, and PCR pro-
ducts were not obtained from all IM and HLH samples.
Conclusions
In conclusion, this study described the diversity of the
EBV genes and investigated the association between
EBV genotypes and the clinical phenotypes of EBV-
related diseases in Chinese pediatric cases. Type I EBV
was the most prevalent subtype EBV in Chinese pedia-
tric cases and V-val-v1 (EBNA-1) and China1 (LMP-1)
variants were the most dominant variants. There was a
strong linkage between V-val-v1 variant (EBNA-1) and
China1 variant (LMP-1) in type I EBV. The sequence
variation in EBV genes may represent a geographic poly-
morphism since no preferential associations were found
between specific EBV variants and specific diseases. A
more comprehensive exploration of EBV diversity across
its entire genome might allow for the development of a
consensus classification system of EBV variants into var-
iant classes that could guide subsequent studies aimed
at understanding EBV geographic and disease associa-
tions [27].
Methods
Patients and Samples
One hundrard and sixteen peripheral blood specimens
were obtained from pediatric patients in Beijing Chil-
dren’s Hospital Affiliated Capital Medical University.
Eighty four were IM and 32 were EBV-HLH. IM and
HLH were diagnosed according to their respective diag-
nostic criteria [40,41]. All procedures were reviewed and
approved by the Committee of Human Studies at the
Beijing Children’s Hospital affiliated the Capital Medical
University. A written informed consent was obtained
from all patients’ parents.
Thirty four paraffin-embedded tissue samples and five
fresh tissue samples from HL cases were also enrolled
into this study.
DNA extraction
Genomic DNA was extracted from 2 ml whole blood
samples by using a blood genomic DNA isolation kit
(Cat#RT403, Tiangen, China) according to manufac-
turer’s instructions. A QIAamp DNA FFPE Tissue kit
(Cat.No.56404, QIAGEN GmbH, Hilden, Germany)
was used to extract the DNA from the paraffin-
embedded HL tissues following manufacturer’si n s t r u c -
tions. The isolation of DNA from the fresh HL biop-
sies was performed using a phenol-chloroform
extraction method.
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Definition of EBV type I/II
EBV type was determined by PCR with specific primers
for EBNA3C. The sequences and positions of these pri-
mers are as follows: EBNA3C-F, 5’-AGA AGG GGA
GCG TGT GTT GT-3’ (B95-8 coordinate 87651-87670);
EBNA3C-R, 5’-GGC TCG TTT TTG ACG TCG GC-3’
(B95-8 coordinate 87803-87784), which yield an amplifi-
cation product of 153 bp for EBV-I and a product of
246 bp for EBV-II, as previously described [3]. PCR was
performed in 50 ul using 1.5 ul of 10 pM of the forward
and reverse primers, 25 ul 2 × Hotsart Taq PCR Master
Mix (Tiangen, China), 5 ul genomic DNA. The reaction
mixture was initially denatured at 95°C for 5 min fol-
lowed by 35 cycles including denaturation at 95°C for
45 s, annealing at 56°C for 45 s, extension at 72°C for 1
min, and finally elongation at 72°C for 10 min. After
PCR assay, the amplified products were subjected to
electrophoresis in 2% agarose gel and visualized under
ultraviolet light.
EBNA-1 amplification
EBNA-1 C-ter region was amplified by nested PCR. The
primers were from a previous study [1]. PCR was per-
formed in 50 ul contained 1.5 ul of 10 pM of the for-
ward and reverse primers, 25 ul 2 × Hotsart Taq PCR
Master Mix (Tiangen, China), and 1.5 ul genomic DNA.
PCR conditions were the same to the previous study [1].
The amplified fragments were 329 bp.
LMP-1 amplification
The oligonucleotide primers were designed to amplify
the full length of LMP-1. The sequences and positions
of these primers are as follows: LMP-1-F1, 5’-AGG
GAG TGT GTG CCA GTT AAG-3’ (B95-8 coordinate
168053-168073); LMP-1-R1, 5’-CAA ACA CAC GCT
TTC TAC TTC C-3’ (B95-8 coordinate 169679-169700);
LMP-1-FS1, 5’-AGG TTA GTC ATA GTA GCT TAG
CTG-3’ (B95-8 coordinate 168157-168180); LMP-1-RS1,
5’-TCA ACG CAG TCT TAG GTA TCT G-3’ (B95-8
coordinate 168953-168974); LMP-1-FS2, 5’-AGG GAG
TCA TCG TGG TGG TGT-3’ (B95-8 coordinate
168917-168739); LMP-1-RS2, 5’-ACT GCC CTG AGG
ATG GAA CAC-3’ (B95-8 coordinate 169466-169486).
The first round polymerase chain reaction (PCR) was
performed with LMP-1-F1 and LMP-1-R1. 1 ul of 10 pM
of the forward and reverse primers, 12.5 ul 2 × Hotsart
Taq PCR Master Mix (Tiangen, China), and 2 ul genomic
DNA were mixed in a 25 ul reaction. The reaction mixture
was initially denatured at 94°C for 5 min followed by 30
cycles including denaturation at 94°C for 45 s, annealing
at 53°C for 45 s, extension at 72°C for 90 s, and finally
elongation at 72°C for 5 min. The products of the first
round PCR were amplified in the second round PCR with
LMP-1-FS1 and LMP-1-RS2 or with LMP-1-FS1, LMP-1-
RS1 and LMP-1-FS2, LMP-1-RS2 as described above. In
the second round PCR the reaction volume was increased
to 50 ul. The amplified fragments were 1648 and 1330 (or
818 and 786) bp, respectively.
For the paraffin-embedded HL tissues, a short frag-
ment of LMP-1 containing the 30 bp deletion region
was amplified also using the nested PCR. The sequences
and positions of the primers are as follows: del-LMP-
1F1, 5’-CTA GCG ACT CTG CTG GAA AT-3’ (B95-8
coordinate 167934-167915); del-LMP-1R1, 5’-GAG TGT
GTG CCA GTT AAG GT-3’ (B95-8 coordinate 167598-
167617); del-LMP-1F2, 5’- TGG AGG GAG AGT CAG
TCA GGC-3’ (B95-8 coordinate 167643-167663); del-
LMP-1R2, 5’-ATT GAC GGA AGA GGT TGA AAA-3’
(B95-8 coordinate 167897-167877). The first round
polymerase chain reaction (PCR) was performed with
del-LMP-1F1 and del-LMP-1R1. 1 ul of 10 pM of the
forward and reverse primers, 12.5 ul 2 × Hotsart Taq
PCR Master Mix (Tiangen, China), and 6 ul genomic
DNA were mixed in a 25 ul reaction. The reaction mix-
ture was initially denatured at 95°C for 5 min followed
by 30 cycles including denaturation at 94°C for 45 s,
annealing at 56°C for 45 s, extension at 72°C for 1 min,
and finally elongation at 72°C for 10 min. The products
of the first round PCR were amplified in the second
round PCR with del-LMP-1F2 and del-LMP-1R2. In the
second round PCR the reaction volume was increased to
50 ul and the genomic DNA was decreased to 4 ul. The
amplified fragments were 337 and 255 bp, respectively.
Sequence analysis
Sequence analysis was performed on an ABI3730XL
Genetic Analyzer. Sequences were aligned and analyzed
with Bioedit V7.0.9 software. Sequences were compared
with B95.8 reference sequence (GenBank V01555) and
with other isolates from GenBank database. Phylogenetic
tree were made by MEGA V4.0.2 software.
Statistical analysis
SPSS 13.0 for windows was used for statistical elabora-
tion. A Chi-square test or a Fisher’s exact test was used
to compare the distribution of EBV type I and II,
EBNA-1 and LMP-1 variants between the IM, HLH and
HL samples. P-values less than 0.05 were considered to
be significant differences.
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